FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947694535> ?p ?o ?g. }

• W2947694535 abstract "3129 Background: NRG1 rearrangements are oncogenic drivers across several tumor types. Chimeric proteins encoded by NRG1 fusions activate HER3, resulting in heterodimerization with HER2 and activation of downstream signaling. Preclinical and preliminary clinical data suggest that targeting HER3 may be an effective treatment strategy for patients with NRG1 fusion-positive tumors. We aimed to describe the clinical and genomic characteristics of patients identified at our institution with NRG1 fusions. Methods: We analyzed results from prospective targeted exome and/or RNA sequencing performed at Memorial Sloan Kettering between 2014-2018 involving > 30,000 samples. NRG1 fusion-positive tumors were identified and these cases were manually reviewed. Results: NRG1 fusions were detected in 24 patients. Cancer types included lung (N = 9), pancreas (N = 7), breast (N = 5), prostate (N = 1), gallbladder (N = 1), diffuse large B-cell lymphoma (N = 1), and cancer of unknown primary (N = 1). 6/9 lung cancers had mucinous differentiation. The majority of patients were Caucasian (N = 17), half were female (N = 12) and ages ranged from 24-82 years-old. Targeted exome sequencing identified the fusion in 10/23 cases tested, including 2 not confirmed by RNA. The remaining 14 were detected using RNA. Fusion partners included CD74 (N = 6), SLC3A2 (N = 2), SDC4 (N = 2), ATP1B1 (N = 2), FOXA1 (N = 1), SLCA4 (N = 1), ROCK1 (N = 1), TNKS (N = 1), CCND1 (N = 1), PAK1 (N = 1), STAU3 (N = 1), RAD51 (N = 1), CD44 (N = 1), NCOR1 (N = 1), RBPMS (N = 1), and WHSC1L1 (N = 1). Pancreas cancers were KRAS wild-type and lung cancers had no co-occurring alterations in ALK, ROS1, EGFR, RET, MET, RAS, or RAF. All tumors were microsatellite stable. A durable response was achieved with anti-HER3 antibody therapy (GSK2849330) in a patient with a CD74- NRG1-rearranged invasive mucinous adenocarcinoma (previously reported). Four patients treated with an irreversible small molecule HER2 inhibitor (afatinib) did not respond to treatment, suggesting direct targeting of HER3 may be superior to HER2 inhibition in patients with NRG1 fusion-positive tumors. Conclusions: NRG1 fusions occur in several tumor types and may be amenable to targeting with HER3-directed therapy." @default.
• W2947694535 created "2019-06-07" @default.
• W2947694535 creator A5030479930 @default.
• W2947694535 creator A5046345178 @default.
• W2947694535 creator A5053263729 @default.
• W2947694535 creator A5063199354 @default.
• W2947694535 creator A5068193017 @default.
• W2947694535 creator A5078938585 @default.
• W2947694535 creator A5088495181 @default.
• W2947694535 creator A5089952390 @default.
• W2947694535 date "2019-05-20" @default.
• W2947694535 modified "2023-09-25" @default.
• W2947694535 title "Clinicopathologic characteristics of NRG1 fusion-positive cancers: A single-institution study." @default.
• W2947694535 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.3129" @default.
• W2947694535 hasPublicationYear "2019" @default.
• W2947694535 type Work @default.
• W2947694535 sameAs 2947694535 @default.
• W2947694535 citedByCount "0" @default.
• W2947694535 crossrefType "journal-article" @default.
• W2947694535 hasAuthorship W2947694535A5030479930 @default.
• W2947694535 hasAuthorship W2947694535A5046345178 @default.
• W2947694535 hasAuthorship W2947694535A5053263729 @default.
• W2947694535 hasAuthorship W2947694535A5063199354 @default.
• W2947694535 hasAuthorship W2947694535A5068193017 @default.
• W2947694535 hasAuthorship W2947694535A5078938585 @default.
• W2947694535 hasAuthorship W2947694535A5088495181 @default.
• W2947694535 hasAuthorship W2947694535A5089952390 @default.
• W2947694535 hasConcept C126322002 @default.
• W2947694535 hasConcept C143998085 @default.
• W2947694535 hasConcept C71924100 @default.
• W2947694535 hasConceptScore W2947694535C126322002 @default.
• W2947694535 hasConceptScore W2947694535C143998085 @default.
• W2947694535 hasConceptScore W2947694535C71924100 @default.
• W2947694535 hasLocation W29476945351 @default.
• W2947694535 hasOpenAccess W2947694535 @default.
• W2947694535 hasPrimaryLocation W29476945351 @default.
• W2947694535 hasRelatedWork W1123899948 @default.
• W2947694535 hasRelatedWork W1511578121 @default.
• W2947694535 hasRelatedWork W2080772448 @default.
• W2947694535 hasRelatedWork W2107977954 @default.
• W2947694535 hasRelatedWork W2122510960 @default.
• W2947694535 hasRelatedWork W2125868040 @default.
• W2947694535 hasRelatedWork W2155888371 @default.
• W2947694535 hasRelatedWork W2319704925 @default.
• W2947694535 hasRelatedWork W2404785813 @default.
• W2947694535 hasRelatedWork W2623447672 @default.
• W2947694535 hasRelatedWork W2889794813 @default.
• W2947694535 hasRelatedWork W2901045644 @default.
• W2947694535 hasRelatedWork W2942512225 @default.
• W2947694535 hasRelatedWork W2944515601 @default.
• W2947694535 hasRelatedWork W2961566889 @default.
• W2947694535 hasRelatedWork W3120665670 @default.
• W2947694535 hasRelatedWork W3166525641 @default.
• W2947694535 hasRelatedWork W3196557881 @default.
• W2947694535 isParatext "false" @default.
• W2947694535 isRetracted "false" @default.
• W2947694535 magId "2947694535" @default.
• W2947694535 workType "article" @default.